Characterisation of CYP2C8, CYP2C9 and CYP2C19 Polymorphisms in a Ghanaian Population

Overview

Journal BMC Med Genet

Publisher Biomed Central

Specialty Genetics

Date 2009 Dec 4

PMID 19954515

Citations 41

Authors

William Kudzi

Alexander No Dodoo

Jeremy J Mills

Affiliations

Soon will be listed here.

Abstract

Background: Genetic influences on drug efficacy and tolerability are now widely known. Pharmacogenetics has thus become an expanding field with great potential for improving drug efficacy and reducing toxicity. Many pharmacologically-relevant polymorphisms do show variability among different populations. Knowledge of allelic frequency distribution within specified populations can be useful in explaining therapeutic failures, identifying potential risk groups for adverse drug reactions (ADRs) and optimising doses for therapeutic efficacy. We sought to determine the prevalence of clinically relevant Cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2C19 variants in Ghanaians. We compared the data with other ethnic groups and further investigated intra country differences within the Ghanaian population to determine its value to pharmacogenetics studies.

Methods: RFLP assays were used to genotype CYP2C8 (*2, *3, *4) variant alleles in 204 unrelated Ghanaians. CYP2C9*2 and CYP2C19 (*2 and *3) variants were determined by single-tube tetra-primer assays while CYP2C9 (*3, *4, *5 and *11) variants were assessed by direct sequencing.

Results: Allelic frequencies were obtained for CYP2C8*2 (17%), CYP2C8*3 (0%), CYP2C8*4 (0%), CYP2C9*2 (0%), CYP2C9*3 (0%), CYP2C9*4 (0%), CYP2C9*5 (0%), CYP2C9*11 (2%), CYP2C19*2 (6%) and CYP2C19*3 (0%).

Conclusion: Allele frequency distributions for CYP2C8, CYP2C9 and CYP2C19 among the Ghanaian population are comparable to other African ethnic groups but significantly differ from Caucasian and Asian populations. Variant allele frequencies for CYP2C9 and CYP2C19 are reported for the first time among indigenous Ghanaian population.

Citing Articles

Frequencies of CYP2C9 polymorphisms in a Syrian cohort.

Aldiban W, Aljamali M, Youssef L BMC Genomics. 2025; 26(1):140.

PMID: 39948503 PMC: 11823145. DOI: 10.1186/s12864-025-11310-9.

Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach.

Alonso Llorente A, Salgado Garrido J, Teijido Hermida O, Gonzalez Andrade F, Valiente Martin A, Fanlo Villacampa A Heliyon. 2024; 10(7):e28566.

PMID: 38586400 PMC: 10998100. DOI: 10.1016/j.heliyon.2024.e28566.

*2/*2 Genotype is a Risk Factor for Multi-Site Arteriosclerosis: A Hospital-Based Cohort Study.

Xie J, Pan T, Luo W, Zhang S, Fang Y, Xu Z Int J Gen Med. 2023; 16:5139-5146.

PMID: 37954650 PMC: 10637229. DOI: 10.2147/IJGM.S437251.

Effects of high-altitude environment on pharmacokinetic parameters of gliquidone in rats.

Huang L, Zhang X, Luo L, Mu H, Li W, Wang R Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 51(4):389-396.

PMID: 37202102 PMC: 10264973. DOI: 10.3724/zdxbyxb-2022-0129.

CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study.

Cai N, Li C, Gu X, Zeng W, Zhong J, Liu J BMC Cardiovasc Disord. 2023; 23(1):185.

PMID: 37024851 PMC: 10080785. DOI: 10.1186/s12872-023-03207-w.

References

Chowbay B, Cumaraswamy S, Cheung Y, Zhou Q, Lee E . Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003; 13(2):89-95. DOI: 10.1097/00008571-200302000-00005. View

Allabi A, Gala J, Desager J, Heusterspreute M, Horsmans Y . Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003; 56(6):653-7. PMC: 1884305. DOI: 10.1046/j.1365-2125.2003.01937.x. View

Lee C, Goldstein J, Pieper J . Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002; 12(3):251-63. DOI: 10.1097/00008571-200204000-00010. View

Gerbal-Chaloin S, Pascussi J, Pichard-Garcia L, Daujat M, Waechter F, Fabre J . Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001; 29(3):242-51. View

Yasar U, Bennet A, Eliasson E, Lundgren S, Wiman B, de Faire U . Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003; 13(12):715-20. DOI: 10.1097/00008571-200312000-00002. View

White R, Beyth R, Zhou H, Romano P . Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999; 107(5):414-24. DOI: 10.1016/s0002-9343(99)00267-3. View

Dreisbach A, Japa S, Sigel A, Parenti M, Hess A, Srinouanprachanh S . The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005; 18(10):1276-81. DOI: 10.1016/j.amjhyper.2005.04.019. View

Scordo M, Aklillu E, Yasar U, Dahl M, Spina E, Ingelman-Sundberg M . Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 2001; 52(4):447-50. PMC: 2014581. DOI: 10.1046/j.0306-5251.2001.01460.x. View

Parikh S, Ouedraogo J, Goldstein J, Rosenthal P, Kroetz D . Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007; 82(2):197-203. DOI: 10.1038/sj.clpt.6100122. View

10.

Bosch T, Doodeman V, Smits P, Meijerman I, Schellens J, Beijnen J . Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther. 2006; 10(3):175-85. DOI: 10.1007/BF03256456. View

11.

Martinez C, Blanco G, Ladero J, Garcia-Martin E, Taxonera C, Gamito F . Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004; 141(2):205-8. PMC: 1574205. DOI: 10.1038/sj.bjp.0705623. View

12.

Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H . Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 2005; 20(4):300-7. DOI: 10.2133/dmpk.20.300. View

13.

Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem M, Dahoma M, Ribeiro V . CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005; 61(1):15-8. DOI: 10.1007/s00228-004-0871-8. View

14.

Lamba J, Lin Y, Thummel K, Daly A, Watkins P, Strom S . Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002; 12(2):121-32. DOI: 10.1097/00008571-200203000-00006. View

15.

Dandara C, Masimirembwa C, Magimba A, Sayi J, Kaaya S, Sommers D . Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001; 57(1):11-7. DOI: 10.1007/s002280100282. View

16.

Grasmader K, Verwohlt P, Rietschel M, Dragicevic A, Muller M, Hiemke C . Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004; 60(5):329-36. DOI: 10.1007/s00228-004-0766-8. View

17.

Xie H, Prasad H, Kim R, Stein C . CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54(10):1257-70. DOI: 10.1016/s0169-409x(02)00076-5. View

18.

de Morais S, Wilkinson G, Blaisdell J, Nakamura K, Meyer U, Goldstein J . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269(22):15419-22. View

19.

Miners J, Birkett D . Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998; 45(6):525-38. PMC: 1873650. DOI: 10.1046/j.1365-2125.1998.00721.x. View

20.

Schwarz U . Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003; 33 Suppl 2:23-30. DOI: 10.1046/j.1365-2362.33.s2.6.x. View